On vs Sanofi

On signs Mbappé as it preps soccer entry

Swiss sportswear brand On has officially entered the soccer market by signing French superstar Kylian Mbappé as its newest brand ambassador. Mbappé, captain of the French national team and Real Madrid striker, will collaborate with product developers to test and refine future football footwear and apparel, marking a shift from traditional endorsements. The announcement coincided with Thierry Henry's appointment as Director of Football and the expansion of Swiss national player Sydney Schertenleib's role to include product development. On plans to leverage its LightSpray technology for football products, representing its largest step beyond running. Analysts view this as a strong start but caution about challenges competing with Nike and Adidas, citing performance credibility and low margins on cleats.

• On signed Kylian Mbappé as brand ambassador for its football division; financial terms and duration were not disclosed.
• Mbappé will work with product developers to test and refine football footwear and apparel.
• Thierry Henry was appointed Director of Football, a new role at On.

On to Host Investor Day on Tuesday, September 22, 2026

On announced it will host an Investor Day on September 22, 2026. The announcement was added to the newsroom on September 8, 2026.

On launches limited sneaker honoring Federer

On, the Zurich-based sports brand, is releasing a limited edition of its 'THE ROGER Centre Court' sneaker to mark Roger Federer’s induction into the International Tennis Hall of Fame. The campaign includes a film titled 'The Boy from Basel' that traces Federer’s youth, and On will sell the 'International Tennis Hall of Fame Edition' exclusively via on.com starting August 25, 2026. The edition is globally limited to 20,000 pairs and features Ivory and Fern colors, a grass-green insole (reportedly suggested by Federer) and a gold racket emblem on the heel. The article notes Federer has been an investor and brand ambassador for On since 2019 and held a stake following On’s 2021 IPO.

• On is launching a limited special edition of the model 'THE ROGER Centre Court' to mark Roger Federer’s Hall of Fame induction.
• On will make the 'International Tennis Hall of Fame Edition' available exclusively on on.com from August 25, 2026 (per the article).
• The edition is limited worldwide to 20,000 pairs according to the company statement.

6-K Financial Filing Analysis for Sanofi (2026-09-17)

Am 17. September 2026 reichte Sanofi ein Form 6-K bei der U.S. Securities and Exchange Commission ein, das eine Pressemitteilung vom 14. September 2026 beinhaltet. Die Einreichung kündigt eine neue strategische Partnerschaft zwischen Sanofi und Cheplapharm im Bereich etablierter Medikamente (Mature Medicines) an. Diese Partnerschaft unterstreicht Sanofis kontinuierliche Strategie zur Portfolio-Optimierung, um etablierte pharmazeutische Produkte effizienter zu verwalten oder zu monetarisieren und Ressourcen auf innovative Pipeline-Therapien und Kernwachstumstreiber zu fokussieren.

• Sanofi hat eine strategische Partnerschaft mit Cheplapharm für sein Portfolio an etablierten Medikamenten (Mature Medicines) geschlossen, die am 14. September 2026 per Pressemitteilung bekannt gegeben wurde.
• Die Form 6-K-Meldung wurde am 17. September 2026 offiziell von Alexandra Roger, Head of Legal Corporate & Finance, unterzeichnet und eingereicht.

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Agentic AI Transforming Pharma Marketing for Rare Diseases

This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.

• The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
• Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
• Sanofi is developing a 'lab-in-a-loop' using AI agents to compress discovery work from years to weeks.